Publications and Resources


Rx IP Update
Rx IP Update provides timely reports and commentary on developments in Canadian intellectual property law that are of particular interest to the pharmaceutical industry, including summaries of new cases before the courts. If you have any comments on the content or presentation of Rx IP Update, or if you would like more information on a specific issue, please do not hesitate to contact Gunars Gaikis or Nancy Pei (editor).

RxIP Update - February 2017
RxIP Update - January 2017
RxIP Update -Apotex’s Infringement of AstraZeneca’s Omeprazole Formulation Patent Upheld
RxIP Update - 2016 Year in Review
Rx IP Update - December 2016
RxIP Update - November 2016
RxIP Update - Implications of CETA and Bill C-30 for pharmaceuticals: Special Release
RxIP Update - October 2016
RxIP Update - September 2016
Rx IP Update - August 2016
Rx IP Update - July 2016
Rx IP Update 2016 Mid-Year Highlights
Rx IP Update - June 2016
Rx IP Update - May 2016
Rx IP Update - April 2016
 
Archives 
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
 
Subscribe





submit
A A A